BioXcel Therapeutics Inc [BTAI] stock is trading at $0.37, down -6.83%. An important factor to consider is whether the stock is rising or falling in short-term value. The BTAI shares have gain 7.60% over the last week, with a monthly amount drifted -18.90%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioXcel Therapeutics Inc [NASDAQ: BTAI] stock has seen the most recent analyst activity on February 21, 2024, when UBS downgraded its rating to a Neutral and also revised its price target to $4 from $9. Previously, Mizuho downgraded its rating to Neutral on August 15, 2023, and dropped its price target to $4. On July 17, 2023, downgrade downgraded it’s rating to Neutral. Jefferies downgraded its rating to a Hold and increased its price target to $22 on March 10, 2023. Goldman upgraded its rating to a Neutral but $16 remained the price target by the analyst firm on December 01, 2022. Mizuho started tracking with a Buy rating for this stock on July 07, 2022, and assigned it a price target of $19. In a note dated April 06, 2022, BofA Securities reiterated an Buy rating on this stock but restated the target price of $80.
BioXcel Therapeutics Inc [BTAI] stock has fluctuated between $0.30 and $4.17 over the past year. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. BioXcel Therapeutics Inc [NASDAQ: BTAI] shares were valued at $0.37 at the most recent close of the market. An investor can expect a potential return of 170.27% based on the average BTAI price forecast.
Analyzing the BTAI fundamentals
BioXcel Therapeutics Inc [NASDAQ:BTAI] reported sales of 2.28M for the trailing twelve months, which represents a drop of -37.24%. Gross Profit Margin for this corporation currently stands at 0.04% with Operating Profit Margin at -32.96%, Pretax Profit Margin comes in at -31.19%, and Net Profit Margin reading is -31.19%. To continue investigating profitability, this company’s Return on Assets is posted at -1.45, Equity is 0.98 and Total Capital is -3.21. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3379 points at the first support level, and at 0.3090 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.4079, and for the 2nd resistance point, it is at 0.4490.
Ratios To Look Out For
For context, BioXcel Therapeutics Inc’s Current Ratio is 1.87. On the other hand, the Quick Ratio is 1.81, and the Cash Ratio is 1.58. Considering the valuation of this stock, the price to sales ratio is 8.45.
Transactions by insiders
Recent insider trading involved O’Neill Vincent, that happened on Dec 16 ’24 when 165.0 shares were sold. CEO and President, Mehta Vimal completed a deal on Dec 16 ’24 to sell 3117.0 shares. Meanwhile, Chief Financial Officer Steinhart Richard I sold 577.0 shares on Dec 16 ’24.
